EARLY POST-TRANSFECTIONAL ISOLATION OF CELLS (EPIC) FOR BIOLOGY PRODUCTION
Patent Information
- Application Number
- DE602017087559
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2016-10-07
- Filing Date
- 2017-10-06
- Publication Date
- 2025-01-29
- Estimated Expiration
- 2037-10-06
AI Technical Summary
Current methods for selecting producer cell populations and clones for biologic manufacturing, such as those using methotrexate (MTX), are time-consuming, affect cell viability, and can impact clonal stability.
The method involves transfecting host cells with vectors encoding a selectable polypeptide and a target polypeptide, followed by the early sorting of transfected cells using fluorescence-activated cell sorting (FACS) or magnetic-activated cell sorting (MACS) within 2 to 15 days post-transfection, allowing for the expansion of a sub-population of producer cells in drug-selection-free medium.
This approach is faster and more productive than traditional MTX-based methods, enabling the generation of high-titer clones suitable for both small and large-scale biologic manufacturing with reduced impact on host cell viability and stability.